Madrigal Pharma Adds Another Genetic Medicine to Its Drug Combo Strategy in MASH

Madrigal Pharmaceuticals has licensed rights to an Arrowhead Pharmaceuticals small-interfering RNA therapy designed to address a particular genetic mutation associated with the fatty liver disease MASH. It’s Madrigal’s fourth business development deal of the past year and the company’s second one involving siRNA therapies. The post Madrigal Pharma Adds Another Genetic Medicine to Its Drug…

Read More

Is the Atrium-WakeMed Merger Already Hitting a Wall?

A proposed merger between Atrium Health and WakeMed Health is facing an early delay, with county commissioners having postponed a key vote over transparency concerns. State officials are warning the deal could hurt competition and drive up healthcare costs in the Raleigh area. The post Is the Atrium-WakeMed Merger Already Hitting a Wall? appeared first…

Read More